Thyroid Hormone in the Clinic and Breast Cancer

Aleck Hercbergs, Shaker A. Mousa, Matthew Leinung, Hung Yun Lin, Paul J. Davis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-thyroxine (T4) in patients with advanced solid tumors, including breast cancer, has favorably affected the course of the cancer, particularly when coupled with administration of exogenous 3,5,3′-triiodo-L-thyronine (T3) (euthyroid hypothyroxinemia). We discuss in the current brief review the possible clinical settings in which to consider whether endogenous thyroid hormone—or exogenous thyroid hormone in the patient with hypothyroidism and coincident breast cancer—is significantly contributing to breast cancer outcome.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalHormones and Cancer
DOIs
Publication statusAccepted/In press - Feb 13 2018

Fingerprint

Thyroid Hormones
Breast Neoplasms
Thyronines
Hypothyroidism
Thyroxine
Neoplasms
Thyroid Gland
Breast

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cancer Research

Cite this

Hercbergs, A., Mousa, S. A., Leinung, M., Lin, H. Y., & Davis, P. J. (Accepted/In press). Thyroid Hormone in the Clinic and Breast Cancer. Hormones and Cancer, 1-5. https://doi.org/10.1007/s12672-018-0326-9

Thyroid Hormone in the Clinic and Breast Cancer. / Hercbergs, Aleck; Mousa, Shaker A.; Leinung, Matthew; Lin, Hung Yun; Davis, Paul J.

In: Hormones and Cancer, 13.02.2018, p. 1-5.

Research output: Contribution to journalArticle

Hercbergs, Aleck ; Mousa, Shaker A. ; Leinung, Matthew ; Lin, Hung Yun ; Davis, Paul J. / Thyroid Hormone in the Clinic and Breast Cancer. In: Hormones and Cancer. 2018 ; pp. 1-5.
@article{010d6e554f774ab9be5bbf8f7f274baa,
title = "Thyroid Hormone in the Clinic and Breast Cancer",
abstract = "There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-thyroxine (T4) in patients with advanced solid tumors, including breast cancer, has favorably affected the course of the cancer, particularly when coupled with administration of exogenous 3,5,3′-triiodo-L-thyronine (T3) (euthyroid hypothyroxinemia). We discuss in the current brief review the possible clinical settings in which to consider whether endogenous thyroid hormone—or exogenous thyroid hormone in the patient with hypothyroidism and coincident breast cancer—is significantly contributing to breast cancer outcome.",
author = "Aleck Hercbergs and Mousa, {Shaker A.} and Matthew Leinung and Lin, {Hung Yun} and Davis, {Paul J.}",
year = "2018",
month = "2",
day = "13",
doi = "10.1007/s12672-018-0326-9",
language = "English",
pages = "1--5",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",

}

TY - JOUR

T1 - Thyroid Hormone in the Clinic and Breast Cancer

AU - Hercbergs, Aleck

AU - Mousa, Shaker A.

AU - Leinung, Matthew

AU - Lin, Hung Yun

AU - Davis, Paul J.

PY - 2018/2/13

Y1 - 2018/2/13

N2 - There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-thyroxine (T4) in patients with advanced solid tumors, including breast cancer, has favorably affected the course of the cancer, particularly when coupled with administration of exogenous 3,5,3′-triiodo-L-thyronine (T3) (euthyroid hypothyroxinemia). We discuss in the current brief review the possible clinical settings in which to consider whether endogenous thyroid hormone—or exogenous thyroid hormone in the patient with hypothyroidism and coincident breast cancer—is significantly contributing to breast cancer outcome.

AB - There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-thyroxine (T4) in patients with advanced solid tumors, including breast cancer, has favorably affected the course of the cancer, particularly when coupled with administration of exogenous 3,5,3′-triiodo-L-thyronine (T3) (euthyroid hypothyroxinemia). We discuss in the current brief review the possible clinical settings in which to consider whether endogenous thyroid hormone—or exogenous thyroid hormone in the patient with hypothyroidism and coincident breast cancer—is significantly contributing to breast cancer outcome.

UR - http://www.scopus.com/inward/record.url?scp=85041930206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041930206&partnerID=8YFLogxK

U2 - 10.1007/s12672-018-0326-9

DO - 10.1007/s12672-018-0326-9

M3 - Article

AN - SCOPUS:85041930206

SP - 1

EP - 5

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

ER -